About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 256  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size
This article has been cited by
1Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity
Qingyu Meng,Yong Cheng,Xi Wu,Dan Zhao,Mingwei Zhao,Jianhong Liang
Clinical and Experimental Optometry.2020;103(4)495
[DOI]
2REACTIVATION OF RETINOPATHY OF PREMATURITY AFTER RANIBIZUMAB TREATMENT
Ryan K. Wong,Sasha Hubschman,Irena Tsui
Retina.2015;35(4)675
[DOI]
3Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment
Tsengelmaa Chuluunbat,R.V. Paul Chan,Nan-Kai Wang,Reyin Lien,Yen-Po Chen,An-Ning Chao,Kuan-Jen Chen,Tun-Lu Chen,Yih-Shiou Hwang,Chi-Chun Lai,Wei-Chi Wu
Ophthalmic Surgery, Lasers and Imaging Retina.2016;47(12)1095
[DOI]
4Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment
Wei-Chi Wu,Jane Z. Kuo
Ophthalmic Surgery, Lasers and Imaging Retina.2017;47(12)119
[DOI]
5Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
Marcel N Menke,Carsten Framme,Mathias Nelle,Markus R Berger,Veit Sturm,Sebastian Wolf
BMC Ophthalmology.2015;15(1)119
[DOI]
6Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits
Duygu Cam,Ayse Tulin Berk,Serap Cilaker Micili,Tuncay Kume,Bekir Ugur Ergur,Osman Yilmaz
Current Eye Research.2017;42(2)315
[DOI]
7Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes
Marko M. Popovic,Prem Nichani,Rajeev H. Muni,Kamiar Mireskandari,Nasrin N. Tehrani,Peter J. Kertes
Survey of Ophthalmology.2020;42(2)315
[DOI]
8Primary Intravitreal Ranibizumab for High-Risk Retinopathy of Prematurity
Caroline R. Baumal,Roger A. Goldberg,Jordana G. Fein
Ophthalmic Surgery, Lasers and Imaging Retina.2015;46(4)432
[DOI]
9Efficacy of ultra-low-dose (0.1?mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series
Islam SH Ahmed,Ahmed MA Hadi,Hassan H Hassan
European Journal of Ophthalmology.2020;30(1)40
[DOI]
10Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
Joyce J. T. Chan,Carol P. S. Lam,Madeline K. M. Kwok,Raymond L. M. Wong,Gary K. Y. Lee,Winnie W. Y. Lau,Jason C. S. Yam
Scientific Reports.2016;6(1)40
[DOI]
11Intravitreal Anti-VEGF Therapy as a Treatment for Retinopathy of Prematurity: What We Know After 7 Years
Michael A. Klufas,R. V. Paul Chan
Journal of Pediatric Ophthalmology & Strabismus.2015;52(2)77
[DOI]
12COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
Guoming Zhang,Mingmin Yang,Jian Zeng,Georgios Vakros,Kangjin Su,Miaohong Chen,Huilin Li,Ruyin Tian,Na Li,Song Tang,Honghui He,Wenjing Tan,Xiangmei Song,Runsen Zhuang
Retina.2017;37(4)710
[DOI]
13Retinopathy of prematurity: recent developments in diagnosis and treatment
Birgit Lorenz,Knut Stieger
Expert Review of Ophthalmology.2015;10(2)167
[DOI]
  Feedback 

Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal